Agios Pharmaceuticals' focus is on expanding Pyrukund's label to treat thalassemia and sickle cell disease, targeting multi-billion dollar markets. Despite promising Phase 3 results, safety ...

Agios' ACTIVATE-Kids trial showed 31.6% of mitapivat-treated children met the hemoglobin response endpoint vs. 0% in the placebo group. Agios reported Q4 Pyrukynd revenue of $10.7M, exceeding the ...

Feb. 13, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare diseases, today reported ...

In this article, we are going to take a look at where Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) stands against the other cheap biotech stocks. Biotechnology stocks are among the most volatile in ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Thank you for reporting this station. We will review the data in question. You are about to report this weather station for bad data. Please select the information that is incorrect.

Found the Nissan Almera Tino of your dreams? Now you want to know all about it! With the help of Parkers, you can find out all of the key specs about the Nissan Almera Tino from fuel efficiency in MPG ...